AU4060302A - Hepatitis c virus (HCV) NS5B RNA Polymerase and mutants thereof - Google Patents
Hepatitis c virus (HCV) NS5B RNA Polymerase and mutants thereof Download PDFInfo
- Publication number
- AU4060302A AU4060302A AU40603/02A AU4060302A AU4060302A AU 4060302 A AU4060302 A AU 4060302A AU 40603/02 A AU40603/02 A AU 40603/02A AU 4060302 A AU4060302 A AU 4060302A AU 4060302 A AU4060302 A AU 4060302A
- Authority
- AU
- Australia
- Prior art keywords
- rna polymerase
- nucleic acid
- leu
- hcv
- binding cleft
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28982901P | 2001-05-10 | 2001-05-10 | |
US60289829 | 2001-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4060302A true AU4060302A (en) | 2002-11-14 |
Family
ID=23113281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU40603/02A Abandoned AU4060302A (en) | 2001-05-10 | 2002-05-10 | Hepatitis c virus (HCV) NS5B RNA Polymerase and mutants thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1256628A3 (fr) |
JP (1) | JP2003061685A (fr) |
KR (1) | KR20030002988A (fr) |
AU (1) | AU4060302A (fr) |
CA (1) | CA2382463A1 (fr) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2335700A1 (fr) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic |
DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7148226B2 (en) * | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
WO2004094452A2 (fr) | 2003-04-16 | 2004-11-04 | Bristol-Myers Squibb Company | Peptide d'isoquinoleine macrocyclique inhibiteurs du virus de l'hepatite c |
DK1625154T3 (da) * | 2003-05-09 | 2014-02-24 | Boehringer Ingelheim Int | Hepatitis c virus ns5b-polymeraseinhibitor-bindende lomme |
US7112601B2 (en) | 2003-09-11 | 2006-09-26 | Bristol-Myers Squibb Company | Cycloalkyl heterocycles for treating hepatitis C virus |
MXPA06003141A (es) | 2003-09-22 | 2006-06-05 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c. |
AP2287A (en) | 2003-10-14 | 2011-10-31 | Intermune Inc | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
JP4682155B2 (ja) | 2004-01-21 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ウイルスに対して活性な大環状ペプチド |
DK1718608T3 (da) | 2004-02-20 | 2013-10-14 | Boehringer Ingelheim Int | Virale polymeraseinhibitorer |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
WO2006018725A1 (fr) | 2004-08-18 | 2006-02-23 | Pfizer Inc. | Inhibiteurs de polymerase d'arn dependant d'arn du virus de l'hepatite c et compositions et traitement utilisant ces inhibiteurs |
CN101189230A (zh) | 2005-05-04 | 2008-05-28 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的杂环化合物 |
JP5030947B2 (ja) | 2005-05-13 | 2012-09-19 | ヴァイロケム・ファーマ・インコーポレーテッド | フラビウイルス感染の治療及び予防のための化合物及び方法 |
US8076365B2 (en) | 2005-08-12 | 2011-12-13 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
EP1886685A1 (fr) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X |
KR20090086081A (ko) | 2006-11-15 | 2009-08-10 | 바이로켐 파마 인코포레이티드 | 플라비바이러스 감염의 치료 또는 예방용 티오펜 유사체 |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
AU2008338273B2 (en) | 2007-12-19 | 2014-10-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
FR2933094A1 (fr) * | 2008-06-26 | 2010-01-01 | Univ Joseph Fourier | Mutations dans la proteine ns5b du vhc. |
WO2010039801A2 (fr) | 2008-10-02 | 2010-04-08 | The J. David Gladstone Institutes | Méthodes de traitement d’une infection par le virus de l’hépatite c |
BRPI0922364A2 (pt) | 2008-12-03 | 2017-08-29 | Presidio Pharmaceuticals Inc | Composto, composição farmacêutica e uso de um composto |
PT2373172E (pt) | 2008-12-03 | 2013-10-21 | Presidio Pharmaceuticals Inc | Inibidores de ns5a de hcv |
EP2408449A4 (fr) | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae |
US9150554B2 (en) | 2009-03-27 | 2015-10-06 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
MX2012006026A (es) | 2009-11-25 | 2012-08-15 | Vertex Pharma | Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus. |
WO2011079327A1 (fr) | 2009-12-24 | 2011-06-30 | Vertex Pharmaceuticals Incorporated | Analogues destinés au traitement ou à la prévention d'infections à flavivirus |
JP2013522375A (ja) | 2010-03-24 | 2013-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染を処置または予防するためのアナログ |
EP2550262A1 (fr) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues destinés au traitement ou à la prévention d'infections à flavivirus |
EP2550268A1 (fr) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues pour traiter ou prévenir les infections à flavivirus |
AU2011232348A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
US8877707B2 (en) | 2010-05-24 | 2014-11-04 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
EP2582717A2 (fr) | 2010-06-15 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Mutants de la protéase ns5b du vhc |
EP2585447A2 (fr) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Composés et méthodes pour le traitement ou la prévention d'infections par flavivirus |
WO2012006070A1 (fr) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Composés et méthodes de traitement ou de prévention d'infections à flavivirus |
WO2012006060A1 (fr) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Composés et méthodes de traitement ou de prévention d'infections à flavovirus |
MX2013001869A (es) | 2010-08-17 | 2013-06-28 | Vertex Pharma | Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae. |
US20130302282A1 (en) | 2010-10-26 | 2013-11-14 | Presidio Pharmaceuticals, Inc. | Inhibitors of Hepatitis C Virus |
WO2012107589A1 (fr) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc |
WO2013016501A1 (fr) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Formulations de composés de thiophène |
WO2013016499A1 (fr) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Procédés de préparation de composés du thiophène |
AU2012347785B2 (en) | 2011-12-06 | 2017-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating viral diseases |
EP2827876A4 (fr) | 2012-03-22 | 2015-10-28 | Alios Biopharma Inc | Combinaisons pharmaceutiques comprenant un analogue thionucléotidique |
TW201526899A (zh) | 2013-02-28 | 2015-07-16 | Alios Biopharma Inc | 醫藥組成物 |
CN107330512B (zh) * | 2017-06-16 | 2020-06-16 | 哈尔滨工业大学深圳研究生院 | 预测蛋白质序列的远同源性关系的系统及方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL138804A0 (en) * | 1998-04-02 | 2001-10-31 | Viropharma Inc | Hepatitis c virus ns5b nucleic acids and proteins |
EP1065213A3 (fr) * | 1999-07-02 | 2003-11-05 | Japan Tobacco Inc. | Polymerase de HCV approprié á l'analyse d'une structure cristalline et procédé d'utilisation de celle-ci |
-
2002
- 2002-05-07 EP EP02009387A patent/EP1256628A3/fr not_active Withdrawn
- 2002-05-08 CA CA002382463A patent/CA2382463A1/fr not_active Abandoned
- 2002-05-09 KR KR1020020025659A patent/KR20030002988A/ko not_active Application Discontinuation
- 2002-05-10 JP JP2002135263A patent/JP2003061685A/ja active Pending
- 2002-05-10 AU AU40603/02A patent/AU4060302A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1256628A3 (fr) | 2003-03-19 |
EP1256628A9 (fr) | 2003-04-16 |
JP2003061685A (ja) | 2003-03-04 |
EP1256628A2 (fr) | 2002-11-13 |
KR20030002988A (ko) | 2003-01-09 |
CA2382463A1 (fr) | 2002-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1256628A2 (fr) | ARN polymerase NS5B du virus de la hepatite C et mutants derivés de la polymerase | |
Yamashita et al. | RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region | |
Mamiya et al. | Hepatitis C virus core protein binds to a DEAD box RNA helicase | |
Ng et al. | p28 Bap31, a Bcl-2/Bcl-XL-and procaspase-8–associated protein in the endoplasmic reticulum | |
JP3851819B2 (ja) | カスパーゼの活性化因子 | |
Satoh et al. | Cleavage of hepatitis C virus nonstructural protein 5A by a caspase-like protease (s) in mammalian cells | |
Gallinari et al. | Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A | |
Ahn et al. | Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus | |
WO2001087958A2 (fr) | Structure cristalline de nitfhit en serpentin revelant qu'un tetramere de nit se lie a deux dimeres de fhit | |
JPH10511843A (ja) | E6結合タンパク質 | |
Yi et al. | Delineation of regions important for heteromeric association of hepatitis C virus E1 and E2 | |
EP0846164B1 (fr) | Procede pour tester l'activite proteolytique de polypeptides ayant une activite de protease hcv ns3 et peptides substrats a utiliser dans cette methode. | |
US5989804A (en) | E6 binding proteins | |
US6333186B1 (en) | Modified forms of Hepatitis C NS3 protease for facilitating inhibitor screening and structural studies of protease: inhibitor complexes | |
US6297030B1 (en) | Human Wnt-7a polynucleotides | |
US5958753A (en) | Nucleic acid sequences encoding Bau, a Bin1 interacting protein, and vectors and host cells containing same | |
Kang et al. | Crystallization and preliminary X-ray crystallographic analysis of the helicase domain of hepatitis C virus NS3 protein | |
US20080167385A1 (en) | Crystal Structure of Human Proliferating Cell Nuclear Antigen (Pcna) and Uses Thereof | |
AU6038399A (en) | Novel bag proteins and nucleic acid molecules encoding them | |
Milhon et al. | SmMAK16, the Schistosoma mansoni homologue of MAK16 from yeast, targets protein transport to the nucleolus | |
EP1444522B1 (fr) | Dosage | |
US7148022B2 (en) | Assay for anti-viral agent | |
US20050037476A1 (en) | Modified Wee1, crystals of peptide: inhibitor complexes containing such modified Wee1, and methods of use thereof | |
US20040072999A1 (en) | Novel protein inhibitor of apoptosis proteins | |
US20050131209A1 (en) | Crystallized hnf4 gamma ligand binding domain polypeptide and screening methods employing same |